68Ga-NODAGA-SNA006

DRUG3 trials

Sponsors

SmartNuclide Biopharma, First Hospital of China Medical University

Conditions

CancerPancreatic CancerSolid Tumor

Early Phase 1

A PET Imaging Agent to Assess the Level of Tumor Tissue-infiltrating CD8 + T Cells in Patients With Solid Tumors

CompletedNCT05126927

SmartNuclide BiopharmaSolid Tumor

Start: 2021-11-02End: 2022-08-01Updated: 2023-04-12

Preliminary Trial of SNA014 for Pancreatic Cancer

RecruitingNCT07597772

SmartNuclide BiopharmaPancreatic Cancer

Start: 2025-10-01End: 2026-07-01Target: 12Updated: 2026-05-19

Phase 1

Application of 68Ga-NODAGA-SNA006 Positron Emission Tomography/Computed Tomography (PET/CT) in Tumors

Active, not recruitingNCT07059832

First Hospital of China Medical UniversityCancer

Start: 2024-04-01End: 2028-04-01Target: 30Updated: 2025-07-11

Related Papers

Abstract 5923: Human dose-escalation study of CD8+T-cell infiltration in solid malignancies with68Ga-NODAGA-SNA006 by PET imaging

Cancer Research2025-04-21

Human dose-escalation study of PET imaging CD8<sup>+</sup> T-cell infiltration in solid malignancies with [<sup>68</sup>Ga]Ga -NODAGA-SNA006.

2024-12-105 citations

Pilot study of a novel nanobody <sup>68</sup> Ga-NODAGA-SNA006 for instant PET imaging of CD8<sup>+</sup> T cells.

2022-07-1323 citations